Best $AIRS mgmt has ever sounded in public webcast just now: “Investment community is just starting to see the progress we are making, and we are in the early innings.” Expressed high confidence in their guide, which includes no GLP-1 linked volume despite already being 10-15% of total. Noted path to doubling margins and resuming highly profitable new store growth into “huge population we can’t serve” Signed off by noting the aesthetics industry “is just getting started”

$MRNA shareholders really need to be asking questions here. From yesterday's ASCO paper. "Treatment-related adverse events occurred in 104/104 patients (100%) in the intismeran plus pembrolizumab arm and 42/50 (84%) in the pembrolizumab arm" Every single patient on combo had a treatment-related AE. "Direct functional linkage between post-treatment T-cell clonotypes and specific intismeran-encoded neoantigens remains to be established." 5-yr OS: HR 0.471, CI 0.165-1.345. So INT reducing death risk by 84% is as equally true as INT increasing death risk by 34%. Among the myriad of imbalances in the trial, the ctDNA imbalance is particularly telling. Combo: 13 ctDNA (12.1%). Pembro: 2 ctDNA (4.0%). With only TWO ctDNA-positive patients in the entire control arm, the ctDNA-positive subgroup HR is mathematically "not estimable." So the highest risk subgroup, the patients who biologically need adjuvant therapy most, cannot be analyzed against a control. After 5 years and three publications, we still don't know if INT works in patients with detectable residual disease. The pembro arm has 30% "not evaluable" ctDNA vs 16.8% in combo. 13 percentage points of unknown ctDNA status in the control arm. In an expensive Phase 2 trial run by two of the largest pharma companies in the world, you would expect cleaner biomarker characterization. Is this simply a coincidence? You be the judge of that.

The data published by $MRNA at ASCO makes complete sense. See mgmt's statements from Barclays in March: "Even seeing a 0.8 hazard ratio, I think, would be a clinically meaningful result." Translation: management is already conditioning the market for a Phase 3 HR of 0.75-0.80. Need I even explain what a 0.8 HR in MELANOMA — the friendliest tumor for immunotherapy — implies for NSCLC, RCC, and bladder? cc: @BlueDuckCap

$AIRS announcing 2 more high-profile conferences appearances (5 in 2 months, after no IR effort in prior year). It is almost as if they think their stock is still too cheap. Meanwhile, fundamentals keep getting better. What new could come out of these? 1. Category and company-specific data (search interest, web traffic, social media engagement) continues to strengthen each month 2. The consumer backdrop has improved (rates, oil, spending reports) 3. Interest in new procedures CK tjnues to grow investors.elitebodysculpture…

$XGN valuation makes no sense. A mgmt team with history of value creation, cornering one of the fastest growing diagnostics end markets with test solutions that make sense for the patient (faster diagnosis/treatment), MD (faster timeline to more lucrative treatment solutions and happier, healthier patients) and the payers who save on repeated multi-year doctor visits that otherwise struggle to diagnose illness such as Lupus). And new indications coming in 2027 which will accelerate growth and expand the TAM.

It’s my 19th birthday today, and my birthday wish is Bill Ackman sees this! @BillAckman Dear Bill Ackman, My dream is to become the best investor I can possibly be My name is Caleb. I’m going to be a freshman at the University of Oregon studying accounting and finance while running D1 XC and track Since I was 15 years old, I had one dream, to go D1 To get there, I learned true work ethic I skipped hangouts I sacrificed weekends I trained every single day no matter how I felt Running taught me something most people never learn Consistency and hard work beats everyone else Now I want to bring that same obsession, discipline, and competitiveness into investing and business In my investing journey, I’ve really looked up to you. You’ve become an unofficial mentor to me, similar to how Warren Buffett was for you early on. I’m asking for an opportunity. I’m willing to work harder than anyone else in the world I’ll work for free I’ll scrub floors I just want the chance to learn, contribute, and prove myself I just need a shot, you won’t regret it Thank you!

$ZM owns between 0.5% and 1% of Anthropic. Their core biz continues to grow and throw off cash to tune of $1.9B ttm fcf. 1/3 of their market cap is in cash. If Anthropic is going to eat the world - and it might - or just if Anthropic continues to grow like a weed - which it will - $ZM is worth a lot more.

👀